The life sciences division of Tata Consultancy Services (TCS) Ltd on Monday said that it is collaborating with the Council of Scientific and Industrial Research (CSIR) to design new chemical entities using artificial intelligence (AI) for treating the novel ‘Severe acute respiratory syndrome Coronavirus 2’ (SARS-CoV-2), the source of covid-19, which has severely affected the people and economy across the globe.

CSIR and TCS artificial intelligence
CSIR and TCS Artificial Intelligence

“The TCS life sciences research area is engaged in cutting-edge application oriented research in synthetic biology. De-novo drug candidate design is the first step in a long sequence of steps to find a cure to Covid-19. The collaboration between TCS and CSIR is a standing example of public private partnership in tackling a problem of national importance,” said Ananth Krishnan, chief technology officer, TCS.

According to a TCS Innovation Labs research paper, they employed “deep neural network-based generative and predictive models for de novo design of new small molecules capable of inhibiting the 3CL protease. The generated small molecules were filtered and screened against the binding site of the 3CL protease structure of SARS-CoV-2.”

Based on the screening results and further analysis, the research paper said that they have identified 31 potential compounds as ideal candidates for further synthesis and testing against SARS-CoV-2.

The use of AI has reduced the initial drug design process from years to only few days, according to TCS. Based on the screening results and further analysis, they have identified 31 potential compounds as ideal candidates for further synthesis and testing. They also found that two of their designed compounds showed high similarity to Aurantiamide, a natural product with anti-viral properties.

TCS’s efforts comes at a time when the world is batting against the deadly virus and the research community across the globe is employing diverse approaches to find a new solution or repurpose existing drugs against the proteins in SARS-CoV-2 to treat the virus.

Based on the screening results and further analysis, the research paper said that they have identified 31 potential compounds as ideal candidates for further synthesis and testing against SARS-CoV-2.

The use of AI has reduced the initial drug design process from years to only few days, according to TCS. Based on the screening results and further analysis, they have identified 31 potential compounds as ideal candidates for further synthesis and testing. They also found that two of their designed compounds showed high similarity to Aurantiamide, a natural product with anti-viral properties.

TCS’s efforts comes at a time when the world is batting against the deadly virus and the research community across the globe is employing diverse approaches to find a new solution or repurpose existing drugs against the proteins in SARS-CoV-2 to treat the virus.

Original News From https://www.livemint.com/

1 Comment

  1. Hi,

    I hope you are safe and healthy 🙂

    I’m reaching to write a guest article on your own website and will send you some topics for that.

    In case my ideas interest you, then I will send a post on any one of the topics chosen by you. The article is going to be of terrific quality and is free of cost.

    I’d just need you to provide me a backlink within the article. Looking forward to a reply.

    Thank you!

    Regards.

    Kristel Marquez

Leave A Reply

Please enter your comment!
Please enter your name here